Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025)

Esperion Therapeutics (ESPR) reported Notes Payables of $54.9 million for Q3 2025, little changed quarter-over-quarter from $54.8 million in Q2 2025.

Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025) Analysis & Trends

Esperion Therapeutics has reported Notes Payables for 2 years, with the latest figure at $54.9 million in Q3 2025.

For the quarter ending Q3 2025, Notes Payables changed N/A year-over-year to $54.9 million; the trailing twelve-month figure through Sep 2025 stood at $54.9 million (changed N/A YoY), and the FY2024 full-year result was $54.6 million, changed N/A from the prior year.
Notes Payables for Q3 2025 stood at $54.9 million, roughly flat from $54.8 million in the prior quarter.
The five-year high for Notes Payables was $54.9 million in Q3 2025, with the low at $54.6 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Esperion Therapeutics	49.69 Mn	-118.16 Mn	45.53 Mn

Download Data